Financial Review: SenesTech (NASDAQ:SNES) & Its Competitors

SenesTech (NASDAQ: SNES) is one of 189 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare SenesTech to similar companies based on the strength of its risk, earnings, valuation, analyst recommendations, institutional ownership, dividends and profitability.

Institutional and Insider Ownership

16.1% of SenesTech shares are held by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 27.4% of SenesTech shares are held by company insiders. Comparatively, 14.6% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares SenesTech and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
SenesTech $320,000.00 -$10.79 million -0.50
SenesTech Competitors $262.31 million -$32.11 million -61.06

SenesTech’s peers have higher revenue, but lower earnings than SenesTech. SenesTech is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares SenesTech and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SenesTech -14,473.40% -190.41% -150.12%
SenesTech Competitors -4,483.83% -487.75% -41.30%

Analyst Ratings

This is a breakdown of current ratings and price targets for SenesTech and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SenesTech 0 0 2 0 3.00
SenesTech Competitors 729 2653 6978 151 2.62

SenesTech currently has a consensus price target of $8.50, indicating a potential upside of 1,168.66%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.30%. Given SenesTech’s stronger consensus rating and higher possible upside, equities research analysts clearly believe SenesTech is more favorable than its peers.

Summary

SenesTech beats its peers on 7 of the 12 factors compared.

About SenesTech

SenesTech, Inc. is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes. Using bait stations, ContraPest is dispensed in a palatable liquid formulation that promotes sustained consumption by rodent communities. Its formulation causes both female and male rats to become infertile once they have consumed the dose. The active ingredient in females accelerates the rate at which ovarian follicles (egg structures) are depleted. Once these cells are gone, the animal cannot reproduce. In males, there is a marked reduction in the ability to fertilize eggs and, often complete sterility. ContraPest is designed, formulated and dispensed for handlers and non-target species, such as wildlife and pets in a biodegradable product.

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply